Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5138160 | 1.00 | ALDH1A1 (0.33) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL1267662 | 0.86 | MGAM (0.41) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL3771016 | 0.84 | PRKCA (0.36) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL5017892 | 0.84 | PRKCA (0.36) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL5023333 | 0.81 | ALDH1A1 (0.33) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL5023336 | 0.81 | ALDH1A1 (0.33) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL1269203 | 0.80 | ALDH1A1 (0.36) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL16064815 | 0.80 | CYP1A2 (0.38) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL3778037 | 0.76 | ALDH1A1 (0.35) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL5023297 | 0.76 | ALDH1A1 (0.35) | ALDH1A1CYP3A4ALOX15TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014954-A1 | Pyrrole synthesis | CIBA SPECIALTY CHEMICALS CORP. | 2005-01-20 | — | — | US | disclosed |
| EP-1451179-A1 | PYRROLE SYNTHESIS | Ciba SC Holding AG (CH) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003044011-A1 | PYRROLE SYNTHESIS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014954-A1 | Pyrrole synthesis | PNPO, PPOX, DHPS | ALDH1A1 511/4885CYP3A4 177/4885ALOX15 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.